

Weiguo Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5935627/publications.pdf>

Version: 2024-02-01

57
papers

2,263
citations

270111

25
h-index

263392

45
g-index

62
all docs

62
docs citations

62
times ranked

3230
citing authors

#	ARTICLE	IF	CITATIONS
1	A Targeted Complement Inhibitor CR1g/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation. <i>Frontiers in Immunology</i> , 2022, 13, 746068.	2.2	2
2	CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4 Fatty Acid Oxidation Pathway. <i>Advanced Science</i> , 2022, 9, .	5.6	26
3	Intracellular complement C5a/C5aR1 stabilizes β -catenin to promote colorectal tumorigenesis. <i>Cell Reports</i> , 2022, 39, 110851.	2.9	38
4	FOXM1D potentiates PKM2-mediated tumor glycolysis and angiogenesis. <i>Molecular Oncology</i> , 2021, 15, 1466-1485.	2.1	30
5	An Integrated Analysis of C5AR2 Related to Malignant Properties and Immune Infiltration of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 736725.	1.3	7
6	Lung mesenchymal stromal cells influenced by Th2 cytokines mobilize neutrophils and facilitate metastasis by producing complement C3. <i>Nature Communications</i> , 2021, 12, 6202.	5.8	71
7	Intracellular C3 prevents hepatic steatosis by promoting autophagy and very low density lipoprotein secretion. <i>FASEB Journal</i> , 2021, 35, e22037.	0.2	11
8	Herbal NF- κ B Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis. <i>Frontiers in Oncology</i> , 2021, 11, 751904.	1.3	2
9	C5aR1 is a master regulator in Colorectal Tumorigenesis via Immune modulation. <i>Theranostics</i> , 2020, 10, 8619-8632.	4.6	37
10	Par complex cluster formation mediated by phase separation. <i>Nature Communications</i> , 2020, 11, 2266.	5.8	73
11	PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma. <i>Theranostics</i> , 2020, 10, 3151-3163.	4.6	37
12	Arginine methylation of ribose-5-phosphate isomerase A senses glucose to promote human colorectal cancer cell survival. <i>Science China Life Sciences</i> , 2020, 63, 1394-1405.	2.3	15
13	PI3K activation is enhanced by FOXM1D binding to p110 and p85 subunits. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 105.	7.1	13
14	The new complement inhibitor CR1g/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice. <i>BMC Nephrology</i> , 2019, 20, 424.	0.8	16
15	Overexpression of MTA1 inhibits the metastatic ability of ZR-75-30 cells in vitro by promoting MTA2 degradation. <i>Cell Communication and Signaling</i> , 2019, 17, 4.	2.7	3
16	Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis. <i>Cell Death and Disease</i> , 2019, 10, 8.	2.7	14
17	FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression. <i>Cell Proliferation</i> , 2019, 52, e12553.	2.4	15
18	KRAB-type zinc-finger proteins PITA and PISA specifically regulate p53-dependent glycolysis and mitochondrial respiration. <i>Cell Research</i> , 2018, 28, 572-592.	5.7	27

#	ARTICLE	IF	CITATIONS
19	Complement Inhibitor CR1g/FH Ameliorates Renal Ischemia Reperfusion Injury via Activation of PI3K/AKT Signaling. <i>Journal of Immunology</i> , 2018, 201, 3717-3730.	0.4	24
20	Nuclear lactate dehydrogenase A senses ROS to produce β -hydroxybutyrate for HPV-induced cervical tumor growth. <i>Nature Communications</i> , 2018, 9, 4429.	5.8	115
21	CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair. <i>Cell Death and Disease</i> , 2018, 9, 887.	2.7	29
22	CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance. <i>Stem Cell Reports</i> , 2017, 8, 140-151.	2.3	29
23	The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer. <i>International Journal of Oncology</i> , 2016, 48, 2015-2024.	1.4	27
24	Complement component 6 deficiency increases susceptibility to dextran sulfate sodium-induced murine colitis. <i>Immunobiology</i> , 2016, 221, 1293-1303.	0.8	5
25	Inhibition of Complement Retards Ankylosing Spondylitis Progression. <i>Scientific Reports</i> , 2016, 6, 34643.	1.6	26
26	Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. <i>Journal of Neuroinflammation</i> , 2016, 13, 23.	3.1	76
27	Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1350-1357.	0.8	557
28	A simple PCR-based method for the rapid genotyping of inherited fifth complement component (C5)-deficient mice. <i>Experimental Animals</i> , 2015, 64, 261-268.	0.7	4
29	Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination. <i>Scientific Reports</i> , 2015, 5, 18099.	1.6	9
30	MAE4, an eLtaS monoclonal antibody, blocks <i>Staphylococcus aureus</i> virulence. <i>Scientific Reports</i> , 2015, 5, 17215.	1.6	6
31	NF- κ B and Enhancer-binding CREB Protein Scaffolded by CREB-binding Protein (CBP)/p300 Proteins Regulate CD59 Protein Expression to Protect Cells from Complement Attack. <i>Journal of Biological Chemistry</i> , 2014, 289, 2711-2724.	1.6	38
32	Chylous Ascites After Laparoscopic Lymph Node Dissection in Gynecologic Malignancies. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 90-96.	0.3	28
33	A novel CR1 α -targeted complement inhibitor protects cells from complement damage. <i>FASEB Journal</i> , 2014, 28, 4986-4999.	0.2	21
34	The Association Between TP53 Arg72Pro Polymorphism and Lung Cancer Susceptibility: Evidence from 30,038 Subjects. <i>Lung</i> , 2013, 191, 369-377.	1.4	19
35	The Protective Role of CD59 and Pathogenic Role of Complement in Hepatic Ischemia and Reperfusion Injury. <i>American Journal of Pathology</i> , 2011, 179, 2876-2884.	1.9	27
36	Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells. <i>Cellular and Molecular Immunology</i> , 2011, 8, 157-163.	4.8	36

#	ARTICLE	IF	CITATIONS
37	rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2011, 17, 6702-6711.	3.2	42
38	Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis. <i>Cancer Research</i> , 2011, 71, 2298-2307.	0.4	74
39	The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. <i>Blood</i> , 2010, 116, 1613-1622.	0.6	64
40	A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS. <i>Journal of Immunology</i> , 2010, 184, 359-368.	0.4	35
41	Complement Regulator CD59 Protects Against Angiotensin II-Induced Abdominal Aortic Aneurysms in Mice. <i>Circulation</i> , 2010, 121, 1338-1346.	1.6	52
42	Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex. <i>Circulation Research</i> , 2009, 104, 550-558.	2.0	110
43	Generation and phenotyping of <i>Cd59a</i> and <i>Cd59b</i> double-knockout mice. <i>American Journal of Hematology</i> , 2009, 84, 65-70.	2.0	25
44	Balancing role of nitric oxide in complement-mediated activation of platelets from <i>Cd59a</i> and <i>Cd59b</i> double-knockout mice. <i>American Journal of Hematology</i> , 2009, 84, 221-227.	2.0	29
45	Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. <i>Nature Medicine</i> , 2008, 14, 98-103.	15.2	35
46	The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy. <i>Oncologist</i> , 2008, 13, 954-966.	1.9	147
47	Domain 4 of ILY sensitizes antibody therapy on cancer and HIV through abrogating human CD59 function. <i>FASEB Journal</i> , 2008, 22, 522-522.	0.2	5
48	A Novel Intravascular Hemolysis Mouse Model. <i>FASEB Journal</i> , 2008, 22, 607-607.	0.2	0
49	Su.73. Analysis of the Promoters and 5'-Utr of Mouse Cd59 Genes, and of Their Functional Activity in Erythrocytes. <i>Clinical Immunology</i> , 2006, 119, S185.	1.4	0
50	Preparation and Preliminary Application of Monoclonal Antibodies against Trichokirin-S1, a Small Ribosome-inactivating Peptide from the Seeds of <i>Trichosanthes kirilowii</i> . <i>Acta Biochimica Et Biophysica Sinica</i> , 2005, 37, 447-452.	0.9	5
51	Gene cloning, bacterial expression, in vitro refolding, and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg. <i>Protein Expression and Purification</i> , 2005, 41, 341-348.	0.6	20
52	Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins. <i>World Journal of Gastroenterology</i> , 2005, 11, 2088.	1.4	12
53	Preparation and Primary Application of Monoclonal Antibodies against a Novel Ribosome-inactivating Protein Moschatin from Pumpkin Seeds. <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 105-110.	0.9	2
54	Expression of Overlapping PreS1 Fragment Recombinant Proteins for the Determination of Immunogenic Domains in HBsAg PreS1 Region. <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 397-404.	0.9	4

#	ARTICLE	IF	CITATIONS
55	A flexible peptide linker enhances the immunoreactivity of two copies HBsAg preS1 (21-47) fusion protein. <i>Journal of Biotechnology</i> , 2004, 107, 83-90.	1.9	37
56	Purification and characterization of Luffin P1, a ribosome-inactivating peptide from the seeds of <i>Luffa cylindrica</i> . <i>Peptides</i> , 2003, 24, 799-805.	1.2	48
57	Co-delivery of paclitaxel and CXCL1 shRNA via cationic polymeric micelles for synergistic therapy against ovarian cancer. <i>Polymer International</i> , 0, , .	1.6	2